Abstract: An example system includes an imaging device and an enclosure substantially separating the imaging device from an outside environment. The enclosure includes an air intake to force air into the enclosure and an aperture to allow air to escape the enclosure. The air intake and the aperture maintain an air pressure level in the enclosure greater than an air pressure of the outside environment.

Abstract: The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1:1) to about nine-to-one (9:1), more preferably a range of about three-to-two (3:2) to about six-to-one (6:1), and most preferably in a range of about two-to-one (2:1) to about four-to-one (4:1) by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release product which has two portions: a first portion having an immediate release formulation of guaifenesin and a second portion having a sustained release formulation of guaifenesin.

Abstract: A hydrant drainage boot is installed around a water supply line and a frost-free hydrant to prevent dirt and debris from blocking the drainage port, and ensures unobstructed drainage of the hydrant. The frost-free hydrant has a linear riser pipe having a pipe top end and a pipe bottom end, a pivoting operating lever having a spigot a valve having a drain port, and a pipe connector. The hollow boot body has a first housing and a second housing attached to form a boot body with a boot cavity, base drainage slots, side drainage slots, water drainage louvers, raised louvers, and input and output ports. The hydrant drainage boot is enclosed around at least the valve, the pipe connector, a water supply line and a portion of the riser pipe of the frost-free hydrant.

Abstract: Operation of a carriage is controlled to actuate a mechanism. The carriage is controlled according to a feed forward term and a feedback term, to compensate interaction of the carriage with the mechanism. Thus, the carriage is to engage the mechanism at a reduced velocity for quiet operation, and fully and reliably actuate the mechanism without stalling the carriage.

Abstract: A printer having an internal electrical power supply is disclosed herein. A method for controlling power consumption in the printer includes receiving an image to be printed, calculating an estimated temperature of the printer, and controlling a speed of the printer to control the power consumption to keep a temperature of the printer below a predetermined maximum temperature in response to the estimated temperature.

Abstract: Operation of a carriage is controlled to actuate a mechanism. The carriage is controlled according to a feed forward term and a feedback term, to compensate interaction of the carriage with the mechanism. Thus, the carriage is to engage the mechanism at a reduced velocity for quiet operation, and fully and reliably actuate the mechanism without stalling the carriage.

Abstract: A printer having an internal electrical power supply is disclosed herein. A method for controlling power consumption in the printer includes receiving an image to be printed, calculating an estimated temperature of the printer, and controlling a speed of the printer to control the power consumption to keep a temperature of the printer below a predetermined maximum temperature in response to the estimated temperature.

Abstract: The invention relates to a novel pharmaceutical modified release formulation of guaifenesin and dextromethorphan. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1:1) to about nine-to-one (9:1), more preferably a range of about three-to-two (3:2) to about six-to-one (6:1), and most preferably in a range of about two-to-one (2:1) to about four-to-one (4:1) by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release product which has two portions: a first portion having an immediate release formulation of guaifenesin and a second portion having a sustained release formulation of guaifenesin, wherein one or both portions further comprises dextromethorphan.

Abstract: The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin and at least one additional drug ingredient. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1:1) to about nine-to-one (9:1), more preferably a range of about three-to-two (3:2) to about six-to-one (6:1), and most preferably in a range of about two-to-one (2:1) to about four-to-one (4:1) by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release product which has two portions: a first portion having an immediate release formulation of guaifenesin and a second portion having a sustained release formulation of guaifenesin, wherein one or both portions has at least one additional drug ingredient.

Abstract: The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin and pseudoephedrine. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1:1) to about nine-to-one (9:1), more preferably a range of about three-to-two (3:2) to about six-to-one (6:1), and most preferably in a range of about two-to-one (2:1) to about four-to-one (4:1) by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release product which has two portions: a first portion having an immediate release formulation of guaifenesin and a second portion having a sustained release formulation of guaifenesin, wherein one or both portions further comprises pseudoephedrine.

Abstract: The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1: 1) to about nine-to-one (9: 1), more preferably a range of about three-to-two (3:2) to about six-to-one (6: 1), and most preferably in a range of about two-to-one (2: 1) to about four-to-one (4: 1) by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release product which has two portions: a first portion having an immediate release formulation of guaifenesin and a second portion having a sustained release formulation of guaifenesin.

Abstract: The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1:1) to about nine-to-one (9:1), more preferably a range of about three-to-two (3:2) to about six-to-one (6:1), and most preferably in a range of about two-to-one (2:1) to about four-to-one (4:1) by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release product which has two portions: a first portion having an immediate release formulation of guaifenesin and a second portion having a sustained release formulation of guaifenesin.

Abstract: A method of controlling a DC motor is presented. In a determining action, a thermal power dissipation is determined from a motor input and a motor velocity. In another determining action, a motor temperature is determined based on a thermal model using the thermal power dissipation. In an adjusting action, a usage of the motor is adjusted, taking the motor temperature into account.

Abstract: The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin and at least one additional drug ingredient. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1:1) to about nine-to-one (9:1), more preferably a range of about three-to-two (3:2) to about six-to-one (6:1), and most preferably in a range of about two-to-one (2:1) to about four-to-one (4:1) by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release product which has two portions: a first portion having an immediate release formulation of guaifenesin and a second portion having a sustained release formulation of guaifenesin, wherein one or both portions has at least one additional drug ingredient.

Abstract: A media handling system for handling sheets of media. The system includes a pick roller having a circumferential media-contacting surface and arranged for rotation about a roller axis to contact and pick a sheet from an input source. A drive roller rotates about a drive roller axis, with a media path extending between the pick roller and the drive roller. A first guide structure is positioned along a first longitudinal edge of the media path and providing a first media guide surface. A second guide structure is positioned along a second longitudinal edge of the media path and provides a second media guide surface. The first and second guide surfaces are positioned to constrain the movement of a media sheet in the media path between the pick roller and the drive roller, thereby alleviating trailing edge print defects.

Abstract: A method of controlling a DC motor is presented. In a determining action, a thermal power dissipation is determined from a motor input and a motor velocity. In another determining action, a motor temperature is determined based on a thermal model using the thermal power dissipation. In an adjusting action, a usage of the motor is adjusted, taking the motor temperature into account.

Abstract: The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin and pseudoephedrine. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1:1) to about nine-to-one (9:1), more preferably a range of about three-to-two (3:2) to about six-to-one (6:1), and most preferably in a range of about two-to-one (2:1) to about four-to-one (4:1) by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release product which has two portions: a first portion having an immediate release formulation of guaifenesin and a second portion having a sustained release formulation of guaifenesin, wherein one or both portions further comprises pseudoephedrine.

Abstract: The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1:1) to about nine-to-one (9:1), more preferably a range of about three-to-two (3:2) to about six-to-one (6:1), and most preferably in a range of about two-to-one (2:1) to about four-to-one (4:1) by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release product which has two portions: a first portion having an immediate release formulation of guaifenesin and a second portion having a sustained release formulation of guaifenesin.

Abstract: A method for reducing a servicing noise is provided. In a measuring action, a servicing position is measured using a full pushing force of an actuator applied to a service station. In a disengaging action, the actuator is disengaged from the service station. In a reducing action, the pushing force is reduced to a minimum value. In an engaging action, the service station is engaged with the actuator. In a monitoring action, a position of the actuator is monitored during the engagement. In a comparing action, the actuator position is compared to the stored servicing position. In an increasing action, the pushing force is increased for future engagements if the servicing position has not been reached. A printing mechanism configured to employ such a method is also provided.

Abstract: A semi-automatic round baler having an “auto kick” or “auto wrap” mode. In the auto kick mode, at the conclusion of the forming cycle the baler will stop and await the operator's signal to continue. Once the operator has signaled to continue, the baler will wrap the bale and will immediately proceed to the ejecting cycle. In auto wrap mode, the baler will automatically enter into and complete the wrapping cycle (after a short delay) following completion of the forming cycle. At the conclusion of the wrapping cycle in the auto wrap mode, the baler will await the operator's signal before ejecting the completed bale.